Citation

McGarry A, Auinger P, Kieburtz KD, Bredlau AL, Hersch SM, Rosas HD. Neurol. Clin. Pract. 2022; 12(2): 131-138.

Copyright

(Copyright © 2022, Lippincott Williams and Wilkins)

DOI

10.1212/CPJ.0000000000001161

PMID

35747889

PMCID

PMC9208406

Abstract

BACKGROUND AND OBJECTIVES: Suicidality is a common concern in the routine care of persons with Huntington disease (HD) and for the many participants in HD clinical trials. In a previous analysis, we identified baseline and time-dependent factors associated with suicidal ideation and attempts from 2CARE, a large, randomized, double-blind clinical trial.

METHODS: The present analysis extends our prior methodology to 2 other large interventional HD clinical trials, CARE-HD and CREST-E.

RESULTS: We observed relationships across studies between suicidality events and prior suicidal ideation at baseline, antidepressant/anxiolytic use, chorea, increasing age, and several domains in the Unified Huntington Disease Rating Scale (UHDRS) Behavioral Assessment (depressed mood, low self-esteem, aggression, and active suicidality).

DISCUSSION: These data may form the basis for a subscale of demographic and UHDRS items with the potential for prospectively identifying suicidality risk in HD clinics and clinical trials. TRIAL REGISTRATION INFORMATION: 2CARE and CREST are registered at clinicaltrials.gov. 2CARE NCT00608881, registered February 6, 2008; first enrollment March 2008. CREST-E NCT00712426, registered July 10, 2008; first enrollment September 2009. CARE-HD, not registered; first enrollment July 1997.

Language: en